Shenzhen Salubris Pharmaceuticals Co., Ltd.
Clinical trials sponsored by Shenzhen Salubris Pharmaceuticals Co., Ltd., explained in plain language.
A Chinese pharmaceutical company developing cardiovascular and oncology drugs.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- Can a daily pill tame a hidden heart risk? Results expected Sep 2026 (estimated)
- Can a daily pill slash high lipoprotein(a) — a hidden heart risk with no approved treatment? Results expected Dec 2026 (estimated)
- New hope for stubborn high blood pressure: experimental drug SAL0140 enters phase 2 trial Results expected Mar 2027 (estimated)
- New drug SAL0140 aims to tame Hormone-Driven high blood pressure Results expected Apr 2027 (estimated)
- Can a new pill tame high cholesterol? a phase 1 trial puts SAL0167 to the test Results expected Jul 2027 (estimated)
-
Can a new pill tame blood pressure that Won't budge?
Disease control CompletedThis trial tests an experimental pill called SAL0120, taken once a day, in adults whose blood pressure stays high even when they already take two or more blood pressure medicines. About 256 people aged 18 to 75 with uncontrolled or resistant hypertension will receive either a low…
Phase 3 • Sponsor: Shenzhen Salubris Pharmaceuticals Co., Ltd. • Aim: Disease control
Last updated Aug 29, 2026 00:00 UTC
-
New combo pill aims to tame stubborn high blood pressure
Disease control CompletedThis phase 3 trial tests whether adding Sacubitril/Allisartan to amlodipine can lower blood pressure more effectively than amlodipine alone in people with essential hypertension. Participants are adults aged 18–75 whose blood pressure remains high despite taking amlodipine. The s…
Phase 3 • Sponsor: Shenzhen Salubris Pharmaceuticals Co., Ltd. • Aim: Disease control
Last updated Jul 17, 2026 00:00 UTC
-
New drug combo aims to tame stubborn high blood pressure
Disease control CompletedThis phase 3 trial tests whether adding amlodipine to Sacubitril/Allisartan can lower blood pressure more effectively than Sacubitril/Allisartan alone in people with essential hypertension. Participants whose blood pressure remains high after four weeks on Sacubitril/Allisartan a…
Phase 3 • Sponsor: Shenzhen Salubris Pharmaceuticals Co., Ltd. • Aim: Disease control
Last updated Jul 17, 2026 00:00 UTC
-
New shot shows promise in lowering 'Bad' cholesterol in large trial
Disease control CompletedThis Phase 3 study tested a new injectable drug called SAL003 in 618 adults with high cholesterol or mixed dyslipidemia. Participants received either SAL003 or a placebo every 4 weeks for 12 weeks, then all received SAL003 for another 40 weeks. The main goal was to see if SAL003 …
Phase 3 • Sponsor: Shenzhen Salubris Pharmaceuticals Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:05 UTC
-
New shot could help lower stubborn high cholesterol
Disease control CompletedThis study tested a new injectable drug called SAL003, given together with the common cholesterol pill atorvastatin, in 214 adults with high cholesterol or mixed dyslipidemia. The goal was to see if the combination lowers 'bad' LDL cholesterol more than atorvastatin alone. Partic…
Phase 2 • Sponsor: Shenzhen Salubris Pharmaceuticals Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC
-
New shot could help lower stubborn high cholesterol
Disease control CompletedThis Phase 3 trial tested an injectable drug called SAL003 in 720 adults with high cholesterol or mixed dyslipidemia. Participants were already on statins but still had high LDL cholesterol. The study compared SAL003 to a placebo to see if it safely lowers cholesterol further. Th…
Phase 3 • Sponsor: Shenzhen Salubris Pharmaceuticals Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:00 UTC